Immunocore
IMCR
86 hedge funds and large institutions have $1.25B invested in Immunocore in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 9 closing their positions.
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
62% more capital invested
Capital invested by funds: $770M → $1.25B (+$477M)
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
30% more funds holding
Funds holding: 66 → 86 (+20)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12.34% more ownership
Funds ownership: 47.97% → 60.31% (+12%)
86% less call options, than puts
Call options by funds: $1.39M | Put options by funds: $9.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$48.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.5M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$39.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$34.7M |
| 5 |
Holocene Advisors
New York
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$28.2M |
| 2 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$9.3M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$7.61M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.81M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$2.56M |
IMCR Hedge Fund Activity: Q3 2022 in Review
86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q3 2022, worth a combined $1.25B — up 62% from $770M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IMCR positions and 9 closed out — a net gain of 20 holders — while 26 added to existing stakes and 19 trimmed.
The largest buyer was Cowen and Company, opening a new position worth an estimated $48.2M. The largest seller was Wellington Management Group, cutting an estimated $28.2M.
- 86 institutional investors held Immunocore (IMCR) as of Q3 2022, up from 66 in Q2 2022.
- Funds reported $1.25B of Immunocore stock for Q3 2022, up 62% quarter-over-quarter.
- 29 funds opened new Immunocore positions in Q3 2022 and 9 closed out, a net change of +20 holders.
- The largest Immunocore buyer in Q3 2022 was Cowen and Company, an estimated $48.2M added.
- The largest Immunocore seller in Q3 2022 was Wellington Management Group, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2022.